Transdermal therapeutic systems have been increasingly used in the past two decades. However, cutaneous side effects are fairly common and may result in poor patient compliance. This review article summarizes the spectrum of reactions due to transdermal therapeutic systems and provides a current list of known allergens.
Get full access to this article
View all access options for this article.
References
1.
PolsterAM, WarnerMR, CamisaC. Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis, 1999; 63:154-5.
2.
PoulJ, WestJ, BuchananN, GrahameR. Local action transcutaneous flurbiprofen in the treatment of soft tissue rheumatism. Br J Rheumatol, 1993; 32:1000-3.
3.
BurkmanRT. The transdermal contraceptive system. Am J Obstet Gynecol, 2004; 190(4Suppl):S49-53.
JordanWP. Clinical evaluation of the contact sensitization potential of a transdermal nicotine system (Nicoderm). J Fam Pract, 1992; 34:709-12.
6.
MeikleAW, AnnandD, HunterC, et al.Pretreatment with a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the testosterone transdermal system in hypogonadal men. Proceedings of the 79th meeting of the Endocrine Society; 1997 June 11-14; Minneapolis, MN. Bethesda (MD): Endocrine Society.
7.
WolfR, TuzunB, TuzunY. Adverse skin reactions to the nicotine transdermal system. Clin Dermatol, 1998; 16:617-23.
8.
HurkmansJF, BoddéHE, Van DrielLM, et al.Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application. Br J Dermatol, 1985; 112:461-7.
9.
von BahrB, WahlbergJE. Reactivity to nicotine patches wrongly blamed on contact allergy. Contact Dermatitis, 1997; 37:44-5.
10.
SmithEW, SmithKA, MaibachHI, et al.The local side effects of transdermally absorbed nicotine. Skin Pharmacol, 1992; 5:69-76.
11.
FischerRG, TylerM. Severe contact dermatitis due to nitroglycerin patches. South Med J, 1985; 78:1523-4.
12.
JordanWPJr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat, 1997; 8:108-13.
13.
RossD, ReesM, GodfreeV, et al.Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. BMJ, 1997; 315:288.
14.
BattaK, FouldsIS. Allergic contact dermatitis to oestradiol patches might have been expected. BMJ, 1998; 316:149.
15.
MurrayKB. Hazards of micro-ovens to transdermal delivery system. N Engl J Med, 1984; 210:721.
16.
KligmanAM. The identification of contact allergens by human assay. III. The maximization test: a procedure for screening and rating contact sensitizers. J Invest Dermatol, 1966; 47:393-409.
17.
CorazzaM, MantovaniL, VirgiliA, StrumiaR. Allergic contact dermatitis from a clonidine transdermal delivery system. Contact Dermatitis, 1995; 32:246.
HorningJR, ZawadaET, SimmonsJL, et al.Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. Chest, 1998; 93:941-5.
FisherAA. Dermatitis due to transdermal therapeutic systems. Cutis, 1984; 34:526-31.
30.
van der WilligenAH, OranjeAP, StolzE, van JoostT. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems. J Am Acad Dermatol, 1988; 18(1 Pt 1):146-7.
31.
TrozakDJ. Delayed hypersensitivity to scopolamine delivered by a transdermal device. J Am Acad Dermatol, 1985; 13:247-51.
32.
Van Der WilligenAH, deGraaf, van JoostT. Peri-ocular dermatitis from atropine. Contact Dermatitis, 1987; 17:56-7.
33.
ShoulsJ, ShumKW, GadourM, GawkrodgerDJ. Contact allergy to testosterone in an androgen patch: control of symptoms by preapplication of topical corticosteroid. Contact Dermatitis, 2001; 45:124-5.
34.
BuckleyDA, WilkinsonSM, HigginsEM. Contact allergy to a testosterone patch. Contact Dermatitis, 1998; 39:91-2.
35.
BoehnckeWH, GallH. Type IV hypersensitivity to topical estradiol in a patient tolerant to it orally. Contact Dermatitis, 1996; 35: 187-8.
36.
CarmichaelAJ, FouldsIS. Allergic contact dermatitis from oestradiol in oestrogen patches. Contact Dermatitis, 1992; 26:194-5.
37.
KochP. Allergic contact dermatitis from estradiol and norethisterone acetate in a transdermal hormonal patch. Contact Dermatitis, 2001; 44:112-3.
38.
Panhans-GrossA, GallH, DziukM, PeterRU. Contact dermatitis from estradiol in a transdermal therapeutic system. Contact Dermatitis, 2000; 43:368-9.
39.
LambSR, WilkinsonSM. Contact allergy to progesterone and estradiol in a patient with multiple corticosteroid allergies. Dermatitis, 2004; 15:78-81.
40.
BircherAJ, HowaldH, RufliT. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis, 1991; 25: 230-6.
41.
JordanWP. Clinical evaluation of contact sensitization potential of a transdermal nicotine system (Nicoderm). J Fam Pract, 1992; 34:709-12.
VincenziC, TostiA, CironeM, et al.Allergic contact dermatitis from transdermal nicotine systems. Contact Dermatitis, 1993; 29: 104-5.
44.
FärmG. Contact allergy to nicotine from a nicotine patch. Contact Dermatitis, 1993; 29:214-5.
45.
SloanPA, MoulinDE, HaysH. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage, 1998; 16:102-11.
46.
DonnerB, ZenzM, StrumpfM, et al.Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage, 1998; 15:168-75.
47.
LittJZ, PawlakWA, editors. Drug eruption reference manual. New York: Parthenon Publishing Group; 1997. p. 184.
48.
MuijsersRB, WagstaffAJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs, 2001; 61:2289-307.
49.
AhmedzaiS, BrooksD. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage, 1997; 13:254-61.
FotiC, ConservaA, AntelmiA, et al.Contact dermatitis from peppermint and menthol in a local action transcutaneous patch. Contact Dermatitis, 2003; 49:312-3.
53.
SchwartzBK, ClendenningWE. Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch. Contact Dermatitis, 1988; 18:106-7.
54.
PatrunoC, SuppaF, SarraccoG, BalatoN. Allergic contact dermatitis due to ethyl alcohol. Contact Dermatitis, 1994; 31:124.
55.
KannyG, MoutonC, MorissetM, Anne Moneret-VautrinD. Food allergy to alcohol. Allergy, 2003; 58:535.
56.
OkazawaH, AiharaM, NagataniT, NakajimaH. Allergic contact dermatitis due to ethyl alcohol. Contact Dermatitis, 1998; 38:233.
57.
PecquetC, PradalierA, DryJ. Allergic contact dermatitis from ethanol in a transdermal estradiol patch. Contact Dermatitis, 1992; 27:275-6.
58.
GrebeSK, AdamsJD, FeekCM. Systemic sensitization to ethanol by transdermal estrogen patches. Arch Dermatol, 1993; 129:379-80.
59.
De GrootAC. Patch testing. 2nd ed. Amsterdam: Elsevier; 1994. p. 10, 17, 18, 117, 148, 210, 225, 229, 241.
60.
McBurneyEI, NoelSB, CollinsJH. Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol, 1989; 20:508-10.
61.
DwyerCM, ForsythA. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Dermatitis, 1994; 30:309-10.
62.
LetendrePW, BarrC, WilkinsK. Adverse dermatological reaction to transdermal nitroglycerin. Drug Intell Clin Pharm, 1984; 18: 69-70.
63.
Di LandroA, ValsecchiR, CainelliT. Contact dermatitis from Nitroderm. Contact Dermatitis, 1989; 21:115-6.
64.
HoldinessMR. A review of contact dermatitis associated with transdermal therapeutic systems. Contact Dermatitis, 1989; 20:3-9.
65.
BoekhorstJC. Allergic contact dermatitis with transdermal clonidine. Lancet, 1983; 2:1031-2.
66.
Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multi-center controlled clinical trails. JAMA, 1991; 266:3133-8.
67.
HoganDJ, MaibachHI. Adverse dermatologic reactions to transdermal drug delivery systems. J Am Acad Dermatol, 1990; 22(5 Pt 1):811-4.
68.
WhiteTM, GuidryJR. Rebound hypertension associated with transdermal clonidine and contact dermatitis. West J Med, 1986; 145:104.
WeberMA, DrayerJI. Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system. Am Heart J, 1984; 108:231-6.
71.
DavisG, WinterL. Cumulative irritation study of placebo transdermal estrogen patches. Curr Ther Res, 1987; 42:712-9.
72.
McGriffNJ, CsakoG, KabbaniM, et al.Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: a review of the literature. Pharmacotherapy, 2001; 21: 1425-35.
73.
BerthJJ, LipskyJJ. Transcutaneous drug delivery: a practical review. Mayo Clin Proc, 1995; 70:581-6.
74.
CarmichaelAJ. Skin sensitivity and transdermal drug delivery. A review of the problem. Drug Saf, 1994; 10:151-9.
75.
ItoMK, O'ConnorDT. Skin pretreatment and the use of transdermal clonidine. Am J Med, 1991; 91:425-9.
76.
AmkrautAA, JordanWP, TaskovichL. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol, 1996; 35:27-31.
77.
WilsonDA, KaidbeyK, BoikeSC, JorkaskyDK. Use of topical corticosteroid pre-treatment to reduce the incidence and severity of skin reactions associated with transdermal therapy. Clin Ther, 1998; 20:299-306.
78.
FillingimJM, MatzekKM, HughesEM, et al.Long-term treatment with transdermal clonidine in mild hypertension. Clin Ther, 1989; 11:398-408.
VaillantL, BietteS, MachetL, et al.Skin acceptance of transcutaneous nitroglycerin patches: a prospective study of 33 patients. Contact Dermatitis, 1990; 23:142-5.
81.
HomickJL, KohlRL, ReschkeMF, et al.Transdermal scopolamine in the prevention of motion sickness: evaluation of the time-course of efficacy. Aviat Space Environ Med, 1983; 54:994-1000.
82.
PlaceVA, PowersM, DarleyPE, et al.A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol, 1985; 152:1092-9.
83.
de CetinaTC, ReyesLP. Skin reactions to transdermal estrogen replacement therapy in a tropical climate. Int J Gynaecol Obstet, 1999; 64:71-2.
84.
MulliganSC, MastersonJG, DevaneJG, KellyJG. Clinical and pharmacokinetic properties of transdermal nicotine patch. Clin Pharmacol Ther, 1990; 47:331-7.
85.
AbelinT, BuehlerA, MüllerP, et al.Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet, 1989; 1:7-10.
AbelinT, EhrsamR, Bühler-ReichertA, et al.Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol, 1989; 11:205-14.
88.
HurtRD, LaugerGG, OffordKP, et al.Nicotine-replacement therapy with use of a transdermal nicotine patch—a randomized double-blind placebo-controlled trial. Mayo Clin Proc, 1990; 65: 1529-37.
89.
KornitzerM, BoutsenM, DramaixM, et al.Combined use of nicotine patch and gum in smoking cessation: a placebocontrolled clinical trial. Prev Med, 1995; 24:41-7.
90.
DaughtonDM, HeatleySA, PrendergastJJ, et al.Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy: a randomized, placebo-controlled, double-blind study. Arch Intern Med, 1991; 151:749-52.
91.
GammaitoniAR, DavisMW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother, 2002; 36:236-40.
92.
GammaitoniAR, AlvarezNA, GalerBS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm, 2002; 59:2215-20.
93.
BarbanoRL, HerrmannDN, Hart-GouleauS, et al.Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol, 2004; 61:914-8.
94.
MeierT, WasnerG, FaustM, et al.Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain, 2003; 106:151-8.
95.
MaibachHI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis, 1987; 16:1-8.
96.
De La Fuente PrietoR, Armentina MendinaA, Díez PérezJM. Contact dermatitis from nitroglycerin. Ann Allergy, 1994; 72:344-6.
